...
首页> 外文期刊>RSC Advances >Molecular modeling studies of quinazolinone derivatives as novel PI3K delta selective inhibitors
【24h】

Molecular modeling studies of quinazolinone derivatives as novel PI3K delta selective inhibitors

机译:喹唑啉酮衍生物作为新型PI3Kδ选择性抑制剂的分子建模研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The forced expression of phosphoinositide 3-kinase delta (PI3K delta) in B cells was found to be oncogenic, rendering PI3K delta an attractive drug target for chronic lymphocytic leukaemia. This study aimed to systemically explore the interaction mechanism of novel quinazolinone scaffold-based derivatives as PI3K delta inhibitors using 3D-QSAR, molecular docking, pharmacophore model and molecular dynamics (MD) simulations. The 3D-QSAR models CoMFA, CoMSIA and Topomer CoMFA were established to discover critical structural factors affecting PI3K delta inhibitory activity. The models showed suitable reliabilities (q(2) 0.741, 0.712 and 0.711) and predictive abilities (r(pred)(2) 0.851, 0.738 and 0.828, respectively). Contour maps indicated that the bioactivity of PI3K delta inhibitor was affected most by electrostatic and hydrophobic fields. The Surflex-Dock and pharmacophore model result showed that enhancing the H-bond interaction of the key substituents around the 2-and 4-positions of pyrimidine with Glu826, Val828 and Asp911, as well as the electrostatic interactions of substituents around the 3-position of benzene with Ser831, Asp832 and Asn836, significantly affected the improvement in the activity and stability of the inhibitor. Based on these results, 10 novel PI3K delta inhibitors with higher predicted activity and binding affinity were designed by introducing the heterocycles pyrrolopyridine or purine. 10 ns MD simulations further study the stable docking conformation of designed compounds, which showed strong hydrogen bond interactions with key residues Ser831 and Asp832 in a propeller-like fashion. These results provided strong guidance for the discovery and optimization of novel potent PI3Kd selective inhibitors.
机译:在B细胞中磷酸肌醇3-激酶增量(PI3Kδ的)的强制表达被发现是致癌,渲染的PI3Kδ一个有吸引力的药物靶标用于治疗慢性淋巴细胞白血病。本研究旨在通过3D-QSAR,分子对接,药物模型和分子动力学(MD)模拟来系统性地探讨新型喹唑啉酮支架基础衍生物作为PI3Kδ抑制剂的相互作用机理。建立了3D-QSAR模型COMFA,COMSIA和Topomer COMFA,以发现影响PI3K Delta抑制活动的关键结构因素。该模型显示出合适的可靠性(Q(2)0.741,0.712和0.711)和预测能力(R(P7)(2)0.851,0.738和0.828分别)。轮廓图表明PI3K Delta抑制剂的生物活性受到静电和疏水场的影响。 Surflex-occk和药效线模型结果表明,用Glu826,Val828和Asp911的嘧啶的2和4位围绕嘧啶的钥匙取代基的H键相互作用以及3位围绕3位的取代基的静电相互作用苯与Ser831,ASP832和ASN836的苯显着影响了抑制剂活性和稳定性的改善。基于这些结果,通过引入杂环吡啶吡啶或嘌呤来设计具有更高的预测活性和结合亲和力的10种新型PI3Kδ抑制剂。 10 NS MD模拟进一步研究了所设计的化合物的稳定对接构象,其显示出与螺旋桨式时尚的密钥残留SER831和ASP832的强氢键相互作用。这些结果提供了对新型有效PI3KD选择性抑制剂的发现和优化的强烈指导。

著录项

  • 来源
    《RSC Advances》 |2017年第89期|共15页
  • 作者单位

    Shanghai Inst Technol Sch Chem &

    Environm Engn Shanghai 201418 Peoples R China;

    Shanghai Inst Technol Sch Chem &

    Environm Engn Shanghai 201418 Peoples R China;

    Shanghai Inst Technol Sch Chem &

    Environm Engn Shanghai 201418 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号